Additionally, studies by Allison et al. using murine colon carcinoma and fibrosarcoma models demonstrated that co-administration of anti-CTLA-4 antibodies with tumor lysate-loaded dendritic cells can reduce Tregs, increase CD8+ lymphocytes, inhibit metastatic growth, and prolong survival [121]. Here, CD8A is linked to neoplasm.